Ameliorating COVID-19-related Acute respiratory distress syndrome (ARDS) with the multi-target strategy utilising natural supplements-from in-silico to a randomised controlled clinical trial

Abstract

Background: COVID-19, several issues concerning this global dilemma is still unknown with no efficient cure protocol. Relieve respiratory distress and lung failure in acute and moderate cases of COVID-19 infections and control of the common signs are the major aims of the current research. Methods: Cure options selected reviewing available information of virus life cycle, host cell involved signal-transduction, and evaluation by in-silico experiments using natural available supplements. We randomly assigned non-hospitalised and hospitalized patients in the trial in the following groups: Control (Lopinavir/Ritonavir, Azithromycin, Hydroxychloroquine sulfate, and Naproxen); Intervention (Artemisinin, Hesperidin, Resveratrol, Noscapine, N-Acetyl Cysteine, and Vitamin C). The outcome included all-cause viability and treatment within 10 days and the clinical improvement of infection characteristics defined in X-ray Computed Tomography, blood factors examination, and ordinal elimination of the signs with statistical assessing the results. Results: In-silico results indicated that the supplements interfere with the virus in multi-state behaviour. In the trial, all hospitalised intervention patients were cured within 10 days. One of the hospitalised control patients died. The blood oxygen level, CT scan results for lung cleansing, amount of Lymphocytes, Neutrophil, LDH, PLTs, ESR, and WBC of the intervention patients were effectively improved than control patients. The comparison of symptoms demonstrated a significant elimination in the prevalence of fever, sore throat, chest pain, for intervention patients (5.40±1.80 hospitalisation days; 3.84±0.8 treatment days) rather than the control group (13.25±8.96 hospitalisation days; 8.80±3.51 treatment days). Conclusions: We found improved clinical status in lung treatment and blood characteristics with no mortality for intervention participants.